In this article, we will discuss 11 High Growth Micro-cap Stocks to Buy.

Investing in stocks of companies with market values under $300 million, otherwise known as micro-cap stocks, offers a unique opportunity to get in early on fast-growing businesses. These smaller companies often fly under the radar, which means that fewer analysts cover them and institutional investors pay less attention, creating opportunities for savvy investors to uncover hidden gems. While they carry higher volatility and sometimes lower liquidity than larger stocks, micro-caps can deliver impressive long-term growth and potentially higher returns compared to big companies.

One of the biggest advantages of micro-cap investing is growth potential. Many of these companies are still in the early stages of expansion, giving investors a chance to benefit if they become leaders in their industries. Micro-caps also provide portfolio diversification, as they often operate in niche sectors that don’t move in sync with large-cap stocks. This can help reduce overall risk and make your investments more balanced.

Another benefit is accessibility. Investors can often engage more directly with company leadership, gaining insight into operations and strategic plans. Many micro-cap companies also have high insider ownership, meaning the people running the business have a personal stake in its success—a strong alignment with shareholder interests.

However, micro-cap stocks can experience sharp price swings, trades can be harder to execute without moving the market, and transaction costs can be higher. But for investors willing to be patient and think long term, micro-caps offer a compelling way to participate in exciting industries, discover tomorrow’s market leaders, and potentially achieve strong, risk-adjusted returns.

With this context in mind, here is a list of 11 high growth micro-cap stocks to buy.

Our Methodology

For this article, we screened for stocks with market capitalizations below $300 million. We then selected 11 stocks that had a revenue growth of over 30% in the past five years. The stocks are ranked in ascending order of their revenue growth. We also included the hedge fund sentiment for each stock, which was sourced from Insider Monkey’s database, as of Q3 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

11 High Growth Micro-cap Stocks to Buy

11. Alpine Income Property Trust, Inc. (NYSE:PINE)

Number of Hedge Fund Holders: 7

Market Capitalization: $256.03 million

5-year Revenue Growth: 31.06%

On February 5, B. Riley raised its price target on Alpine Income Property Trust, Inc. (NYSE:PINE) to $21 from $19 while reiterating a Buy rating, pointing to the REIT’s expanding exposure to higher-yielding structured loan investments as a key driver of upside. According to the firm, Alpine’s ability to deploy capital at yields well above those typically available in the net lease space meaningfully improves its earnings profile and positions the company for strong AFFO per share growth in 2026.

That thesis is supported by Alpine’s recent operating performance and capital allocation strategy. During its third-quarter earnings call, the company highlighted continued disciplined growth across both property acquisitions and lending activity. Alpine Income Property Trust, Inc. (NYSE:PINE) acquired properties ground-leased to Lowe’s for $21.1 million at a 6.0% cap rate, underscoring the quality and durability of its tenant base. Year to date, total property acquisition volume reached $60.8 million at an attractive weighted-average cap rate of 7.7%, reflecting management’s focus on acquiring essential-use assets at compelling valuations.

Moreover, Alpine continues to differentiate itself through its structured loan platform. During the quarter, the REIT originated $28.6 million in loans at a weighted-average yield of 10.6%, significantly enhancing portfolio returns while maintaining a conservative risk profile. This blend of stable net lease income and higher-yielding credit investments provides a diversified and flexible earnings engine, particularly valuable in a higher-for-longer rate environment.

Importantly for income-focused investors, Alpine Income Property Trust, Inc. (NYSE:PINE) declared and paid a quarterly cash dividend of $0.285 per share, representing an annualized yield of approximately 8.25%. The dividend remains well covered, with an AFFO payout ratio of just 62%, leaving room for reinvestment and future growth.

Headquartered in Winter Park, Florida, Alpine focuses on single-tenant commercial properties leased to high-quality tenants across essential retail, distribution, and industrial sectors. With disciplined capital deployment, improving yield mix, and a secure dividend, Alpine Income Property Trust, Inc. (NYSE:PINE) appears well-positioned to deliver attractive total returns as earnings momentum builds into 2026.

10. Seven Hills Realty Trust (NASDAQ:SEVN)

Number of Hedge Fund Holders: 3

Market Capitalization: $197.74 million

5-year Revenue Growth: 32.95%

On January 7, Ladenburg initiated coverage of Seven Hills Realty Trust (NASDAQ:SEVN) with a Buy rating and a $10 price target, highlighting improving forward visibility following recent balance sheet actions and portfolio growth initiatives. The initiation comes after a volatile period for the stock, during which shares declined sharply despite management executing on previously outlined strategic objectives.

A key catalyst underpinning the investment thesis is Seven Hills’ fully backstopped transferable rights offering completed on December 11, 2025, which raised $65.2 million in gross proceeds at $8.65 per share. The capital raise was designed to fund portfolio expansion and was quickly deployed into income-generating assets, including three floating-rate first mortgage loans totaling $101.3 million, reflecting disciplined underwriting across diversified commercial real estate asset types. The timely deployment of capital mitigates dilution concerns and positions the REIT to rebuild earnings momentum in the new loan season.

Operationally, Seven Hills Realty Trust (NASDAQ:SEVN) reported softer third-quarter 2025 results, with distributable income of $0.29 per share on $7.1 million in revenue, reflecting pressure from lower net interest margins ahead of the capital raise. However, management reaffirmed confidence in near-term stabilization by closing on the anticipated new investments and guiding to fourth-quarter distributable income of approximately $0.30 per share, sufficient to cover the $0.28 quarterly distribution. Despite the stock’s pullback to multi-year lows in early December, the combination of refreshed capital, portfolio expansion, and improving income coverage supports a more constructive outlook.

Based in Newton, Massachusetts, Seven Hills Realty Trust (NASDAQ:SEVN) focuses on floating-rate first mortgage loans secured by middle-market transitional commercial real estate, a niche that can benefit meaningfully as deployment scales and rate dynamics stabilize, making the recent weakness an opportunity for long-term, income-focused investors.

9. Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Number of Hedge Fund Holders: 15

Market Capitalization: $135.08 million

5-year Revenue Growth: 39.65%

Treace Medical Concepts is one of the high-growth micro-cap stocks to buy. On January 7, Stifel lowered its price target on Treace Medical Concepts, Inc. (NASDAQ:TMCI) to $3 from $5 while maintaining a Hold rating, reflecting a broader recalibration across its MedTech coverage following the pressures seen in 2025. While the firm adjusted targets on several names, it emphasized a more constructive setup for the sector heading into 2026, particularly for large-cap MedTech, even as Treace remains in a transition phase relative to its larger peers.

Operationally, Treace Medical Concepts, Inc. (NASDAQ:TMCI) continues to deliver steady growth. During the third quarter of 2025, the company reported revenue of $50.2 million, representing 11% year-over-year growth. Management is sharpening its focus on expanding the product portfolio, increasing surgeon education and training, and strengthening the sales organization, initiatives aimed at driving incremental market share gains and improving profitability as procedure volumes normalize.

Founded in 2014 and headquartered in Ponte Vedra, Florida, Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a medical technology company dedicated to advancing the standard of care for the surgical treatment of bunion and related midfoot deformities. While near-term investor sentiment remains cautious, the company’s continued revenue growth and strategic investments in commercial execution position it to benefit from an improving MedTech demand backdrop as 2026 unfolds.

8. Gambling.com Group Limited (NASDAQ:GAMB)

Number of Hedge Fund Holders: 18

Market Capitalization: $168.40 million

5-year Revenue Growth: 45.77%

On January 20, Benchmark analyst Mike Hickey lowered the firm’s price target on Gambling.com Group Limited (NASDAQ:GAMB) to $7 from $8 while maintaining a Buy rating, reflecting a more cautious stance on the company’s 2026 earnings trajectory rather than any deterioration in near-term fundamentals. The firm expects fourth-quarter results to come in line with updated 2025 guidance, but flagged rising risk that next year’s results could undershoot current consensus expectations amid a more competitive and maturing online gambling landscape.

Operationally, Gambling.com Group Limited (NASDAQ:GAMB) continues to thrive; during the third quarter of 2025, the company delivered record revenue of $39 million, up 21% year over year, while adjusted EBITDA increased 3% to $13 million. Management also raised full-year expectations, guiding to approximately $165 million in revenue and $58 million in adjusted EBITDA, representing year-over-year growth of 30% and 19%, respectively. These results underscore the scalability of the company’s performance marketing model and its ability to generate strong cash flow even as growth moderates.

Founded in 2006, Gambling.com Group Limited (NASDAQ:GAMB) is a performance marketing and sports betting media company that provides digital customer acquisition services to online gambling operators. With primary operations in Dublin, Ireland, and a significant U.S. presence in Charlotte, North Carolina, the company remains well-positioned to benefit from the continued legalization and expansion of online sports betting, while its asset-light model provides flexibility to navigate potential volatility in 2026.

7. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Number of Hedge Fund Holders: 18

Market Capitalization: $97.69 million

5-year Revenue Growth: 46.10%

On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a selective stance toward SMID-cap biotech heading into 2026. While Citi sees opportunity in commercial or near-commercial stage companies, its broader outlook favored other names, highlighting the importance of upcoming clinical and regulatory catalysts in determining relative upside across the space.

More recently, Arcturus announced the initiation of a first-in-human Phase 1 study for ARCT-2304, a self-amplifying mRNA-based pandemic influenza vaccine. For investors, this represents an early but meaningful inflection point, as it will provide initial human data on whether Arcturus’ proprietary self-amplifying RNA platform can demonstrate competitive immune responses with potentially lower dosing requirements. While any commercial contribution remains several years away, positive safety and immunogenicity data could materially improve Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s strategic positioning by supporting future partnerships, grant funding, or non-dilutive capital. Until clinical results are disclosed, the shares are likely to remain range-bound, with sentiment driven by expectations around data timing and management commentary.

Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is an RNA medicines biotechnology company focused on developing therapies and vaccines for rare diseases and infectious diseases, leveraging its differentiated RNA technology platform to target large, long-term market opportunities.

6. High Tide Inc. (NASDAQ:HITI)

Number of Hedge Fund Holders: 10

Market Capitalization: $97.69 million

5-year Revenue Growth: 46.96%

On February 2, Canaccord analyst Luke Hannan lowered the price target on High Tide Inc. (NASDAQ:HITI) slightly to C$7 from C$7.25, maintaining a Buy rating on the shares. The modest adjustment reflects near-term execution considerations but does not diminish confidence in the company’s strategic expansion plans and long-term growth potential.

High Tide Inc. (NASDAQ:HITI) is actively positioning for growth in both domestic and international markets. In Canada, the company has expanded its Canna Cabana footprint to 218 stores, solidifying its status as the country’s largest cannabis retailer while strengthening its membership-driven model, which supports operating leverage and improved profitability. Management is also exploring U.S. opportunities, including licensing Canna Cabana and developing CBD offerings aligned with potential Medicare coverage, providing a measured entry into the world’s largest cannabis-related market without relying on full federal legalization. Additionally, High Tide has begun expanding internationally, entering Germany’s medical cannabis market, signaling ambitions beyond its Canadian core.

Founded in 2009 and headquartered in Canada, High Tide Inc. (NASDAQ:HITI) is the nation’s largest cannabis retailer by revenue.

5. Outset Medical, Inc. (NASDAQ:OM)

Number of Hedge Fund Holders: 23

Market Capitalization: $88.85 million

5-year Revenue Growth: 49.79%

On January 7, Stifel analyst Rick Wise lowered the price target on Outset Medical, Inc. (NASDAQ:OM) to $8 from $14 while maintaining a Buy rating on the shares. The adjustment reflects near-term pressures in MedTech following 2025, though the firm remains constructive on the sector overall for 2026.

Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In Q3 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Tablo console sales increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.

Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of healthcare’s largest and most expensive segments, through innovative technology, research, and North American manufacturing operations.

4. Evolus, Inc. (NASDAQ:EOLS)

Number of Hedge Fund Holders: 28

Market Capitalization: $296.87 million

5-year Revenue Growth: 50.12%

On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc. (NASDAQ:EOLS) to $15 from $19 while maintaining an Outperform rating, reflecting updated expectations following a softer-than-anticipated preannounced fourth quarter. Despite the near-term adjustment, the continued Outperform stance signals confidence in Evolus’ longer-term growth trajectory and the durability of its competitive positioning within the medical aesthetics market.

Operationally, Evolus, Inc. (NASDAQ:EOLS) continues to demonstrate solid underlying momentum. During its third-quarter 2025 earnings call, the company reported revenue of $69 million, representing 13% year-over-year growth, driven by sustained global demand for Jeuveau and the U.S. launch of Evolysse. These two products anchor Evolus’ expanding portfolio and highlight the company’s ability to execute across both established and newly introduced offerings, supporting revenue diversification and market penetration.

Evolus operates as a performance beauty company focused on injectable aesthetic treatments in the cash-pay market. By building a portfolio of differentiated, physician-led brands and expanding its international footprint, the company is positioning itself for continued share gains over time. Headquartered in Newport Beach, California, and founded in 2012, Evolus, Inc. (NASDAQ:EOLS) appears well placed to translate its growing product portfolio and global demand trends into sustained top-line growth as short-term volatility normalizes.

3. AVITA Medical, Inc. (NASDAQ:RCEL)

Number of Hedge Fund Holders: 6

Market Capitalization: $101.35 million

5-year Revenue Growth: 63.43%

On January 16, Lake Street raised its price target on AVITA Medical, Inc. (NASDAQ:RCEL) to $3.50 from $3 while maintaining a Hold rating, citing the company’s recent debt refinancing as a critical step in alleviating near-term liquidity concerns. The analyst noted that upcoming full Q4 results, along with clearer commentary on reimbursement trends, could serve as important catalysts for investor confidence, though the firm prefers to see further evidence of business stabilization before adopting a more constructive stance.

Looking ahead, AVITA Medical, Inc. (NASDAQ:RCEL) has outlined a more encouraging growth profile, guiding for FY26 revenue of $80 million to $85 million, compared with $71.6 million in FY24. Management has emphasized that the past year was focused on strengthening the company’s foundation by stabilizing revenue, advancing the clinical pipeline, and improving financial flexibility. With these building blocks now in place, Avita expects to transition into a phase of execution-led growth, supported by a healthier balance sheet and upcoming clinical and commercial milestones.

AVITA Medical, Inc. (NASDAQ:RCEL) is a regenerative medicine company developing and commercializing innovative therapeutic solutions, with a focus on improving outcomes in complex wound and tissue repair. Founded in 1999 and headquartered in Santa Clarita, California, the company enters 2026 with an improved financial footing and a clearer path toward more predictable, scalable performance as it works to convert stabilization efforts into sustained growth.

2. SKYX Platforms Corp. (NASDAQ:SKYX)

Number of Hedge Fund Holders: 1

Market Capitalization: $289.33 million

5-year Revenue Growth: 86.64%

On January 22, Roth Capital analyst Gerry Sweeney raised the firm’s price target on SKYX Platforms Corp. (NASDAQ:SKYX) to $5 from $4.25 while maintaining a Buy rating, citing steady execution across the company’s strategic roadmap and growing confidence that Skyx is approaching a key inflection point. The analyst highlighted recent progress in securing new product placements, strengthening the company’s e-commerce strategy, and expanding distribution channels, all of which are expected to support improving scale and margin expansion over time.

Operational momentum continues to build. During its third-quarter 2025 earnings call, Skyx reported record revenue of $24 million, marking its seventh consecutive quarter of revenue growth and underscoring increasing adoption of its product portfolio. The company is also preparing to launch a new AI-driven software platform designed to enhance both B2B and B2C customer experiences, with management expecting the technology to lift e-commerce conversion rates by roughly 30%. This initiative positions SKYX Platforms Corp. (NASDAQ:SKYX) to better monetize its growing online presence while driving higher-margin digital sales.

Skyx Platforms specializes in smart, safe, and easy-to-install plug-and-play technologies for lighting and ceiling fan applications, including interactive canopies and smart lighting bases. By combining innovative hardware with software-enabled functionality, the company is addressing demand for modernized home and commercial lighting solutions while simplifying installation and improving safety standards. Founded in 2004 and headquartered in Pompano Beach, Florida, SKYX Platforms Corp. (NASDAQ:SKYX) appears increasingly well-positioned to translate its expanding distribution footprint, product innovation, and technology investments into sustained revenue growth and improved profitability as it moves toward its next phase of scale.

1. Vivid Seats Inc. (NASDAQ:SEAT)

Number of Hedge Fund Holders: 9

Market Capitalization: $97.69 million

5-year Revenue Growth: 116.85%

Vivid Seats is among the high-growth micro-cap stocks to buy. On January 20, Deutsche Bank lowered its price target on Vivid Seats Inc. (NASDAQ:SEAT) to $7 from $18 while maintaining a Hold rating, reflecting a more cautious near-term view amid a challenging discretionary spending backdrop for live events and ticketing platforms. While the adjustment underscores ongoing volatility in the secondary ticketing market, it does not negate the company’s strategic efforts to strengthen its operating and financial foundation for longer-term growth.

A key recent development supporting that effort is the appointment of Joseph Thomas as chief financial officer, effective January 19, 2026. Thomas brings a blend of operational, e-commerce, and capital markets experience from his prior role as CFO of Reliable Parts, as well as a background in private equity and M&A. This profile positions him well to enhance Vivid Seats Inc. (NASDAQ:SEAT)’ financial discipline, optimize capital allocation, and support strategic initiatives such as margin improvement, balance sheet management, and potential inorganic growth. Leadership continuity is also preserved, with former interim CFO Edward Pickus remaining as chief accounting officer, ensuring stability during the transition.

Founded in 2001 and headquartered in Chicago, Vivid Seats Inc. (NASDAQ:SEAT) operates a leading online ticket marketplace and resale platform and serves as the official ticketing partner for prominent organizations, including ESPN, United Airlines, the San Francisco 49ers, and the Los Angeles Chargers. As the company continues to refine its financial strategy and leverage its strong brand partnerships, the combination of experienced leadership and a scaled platform could help position Vivid Seats to benefit as demand for live entertainment normalizes and consumer spending conditions improve over time.

While we acknowledge the potential of SEAT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SEAT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.